Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LAKE OSWEGO, Ore., Oct. 4, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:RXII), a biotechnology company focused on developing innovative, targeted oncology treatments that address major...
-
Galena Biopharma(TM) to Focus on Targeted Cancer Therapies RXi Pharmaceuticals to Focus on RNAi-Based Therapeutics Separation of oncology and RNAi programs expected to enhance shareholder...
-
Vaccine targets Folate Binding Protein (FBP) which is over-expressed in more than 90% of ovarian cancers and in the majority of other adenocarcinomas. RXi plans to initiate Phase 1 clinical...
-
The CMC partial clinical hold has been lifted by the FDA, allowing the pivotal Phase 3 trial to commence. RXi has assigned a principal investigator and initial IRB approvals received--going...
-
WORCESTER, Mass., Sept. 8, 2011 (GLOBE NEWSWIRE) -- RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies...
-
WORCESTER, Mass., Sept. 7, 2011 (GLOBE NEWSWIRE) -- RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies...
-
NeuVax™ (E75) makes significant progress towards initiating the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2...
-
WORCESTER, Mass., Aug. 12, 2011 (GLOBE NEWSWIRE) -- RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies...